CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer. For patients with metastatic kidney cancer, a multidisciplinary approach ...

Highlights in metastatic kidney cancer research from the 2023 International Kidney Cancer Symposium include promising data on zanzalintinib, a dose-finding study on belzutifan, and further ...

At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...

A protein identified by researchers at UT Southwestern Medical Center may drive resistance to immune checkpoint inhibitors, a widely used form of immunotherapy to treat cancer. The findings, published ...

A team of CNIO researchers, in collaboration with the Spanish Oncology Genitourinary Group (SOGUG) and the University Hospitals Leuven (Belgium), has discovered various potential biomarkers predictive ...

Anticipated findings from the LITESPARK-011 trial (NCT04586231) to be presented during the 2026 ASCO Genitourinary Cancers ...

UCLA researchers have developed a new kind of immunotherapy that uses specially engineered immune cells equipped with built-in weapons to attack kidney cancer tumors and reprogram their protective ...

Study documents low use of immune checkpoint inhibitor-based combinations for first-line treatment of metastatic clear cell RCC and high attrition with subsequent therapy. Many patients with ...

Temporal patterns in renal cancer mortality: A 20-year analysis of US-Mexico border states. Cytoreductive nephrectomy for patients with metastatic non-clear cell renal cell carcinoma: Results from a ...

Mortality risk in clinical T1a renal cell carcinoma (RCC) with synchronous metastasis (SM): A comparative analysis of National Cancer Database (NCDB). This is an ASCO Meeting Abstract from the 2025 ...

The treatment landscape for clear cell renal cell carcinoma (ccRCC) could be due for a shake-up following dual breakthroughs ...